Naptumomab Estafenatox

Preferred Label : Naptumomab Estafenatox;

NCIt definition : A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120), with immunomodulating and antineoplastic activities. The Fab moiety of naptumomab estafenatox binds to 5T4, an antigen expressed by various tumor cells. In turn, the superantigen binds to both major histocompatibility complex class II molecules and to the T-cell receptor beta chain, which results in a massive activation of T lymphocytes and induces a potent T-cell-mediated killing of tumor cells.;

UNII : 93T929W6LC;

CAS number : 676258-98-3;

Molecule name : ABR-217620;

Détails

Origin ID

C95789;

UMLS CUI

C2742795;

Currated CISMeF NLP mapping
- naptumomab estafenatox [MeSH concept]
- naptumomab estafenatox [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
UMLS correspondences (same concept)
- naptumomab estafenatox [MeSH concept]
- naptumomab estafenatox [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients